



COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks

Rashed Noor¹ · Nishat Tasnim¹ · Chandrika Saha¹

Accepted: 7 June 2021 / Published online: 3 July 2021

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021

Abstract

Purpose of Review COVID-19 pandemic has been the major threat to the global public health for a year (last of 2019–till date); and unfortunately, there is still as no specific antiviral agent which can be effectively used against this disease curation. Present review focused on the application of the convalescent plasma (CP) therapy as a quick remediation of the disease severity.

Recent Findings While several drugs have been repurposed based on a number of completed clinical trials together with a huge ongoing effort to develop appropriate vaccine against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the therapeutic approach of the CP therapy appears to be one of the effective methods to rescue the severely affected COVID-19 patients. Such a therapy based on passive immunity evolved from the SARS-CoV-2-infected patients who have fully recovered from COVID-19; and hence these individuals are quite likely to possess high titers of the SARS-CoV-2-neutralizing immunoglobulins (antibodies). However, there are some risks such therapy, and its effectivity also appeared doubtful in some cases. Thus, the current review discussed the issues raised by the administration of such plasma into the SARS-CoV-2-infected individuals.

Summary Application of CP therapy has been conducted since long time; and for the mitigation of COVID-19 severity, such pharmaceutical strategy is also being employed in spite of several risks which actually can be monitored as well as optimized in order to combat the SARS-CoV-2 infection.

Keywords COVID-19 pandemic · SARS-CoV-2 · Convalescent plasma (CP) therapy

Introduction

Convalescent plasma (CP) therapy or the passive antibody therapy, which has been implemented for over a century, is known to involve the administration of antibodies against a specific pathogen or a group of pathogens to a susceptible individual in order to mitigate the infectious disease(s) [1, 2]. Indeed, such forms of passive immunity were the only means of treating infectious diseases prior to the development of the successful antimicrobial therapy [2, 3]. In case of failure of designing/obtaining appropriate drug(s) or vaccine(s), the infecting

pathogen can be indirectly utilized which is obviously capable to instigate the immune response producing the neutralizing antibodies [4]. Passive transfusion of the convalescent blood products (CBPs), prepared by collecting usually the whole blood from a convalescent donor (the person who has recovered from the infection), has been known to be as a feasible therapeutic strategy for more than hundred years effectiveness especially in lowering the mortality rate of the COVID-19 patients in the current days [5–7]. The objective of CBP of the CP therapy is the complete elimination of viruses (typically within 10 to 14 days after infection) in the recipient patient [4, 6]. Besides, the transfusion of influenza-convalescent human blood products was found to reduce the mortality rate during the Spanish influenza whereby the treatments for H5N1 influenza were disappointing, but the convalescent human plasma consisting of the H5N1 was found to be an effective therapeutic strategy [2]. At present, passive antibody therapy depends mainly on pooled immunoglobulin (antibody) preparations usually of high titer, whereas the plasma therapy is employed in case of epidemic/pandemic emergency cases where there is insufficient time or resources to produce antibodies [1]. There

This article is part of the Topical Collection on *Virology*

✉ Rashed Noor
rashednoor@iub.edu.bd

¹ Department of Life Sciences (DLS), School of Environment and Life Sciences (SELS), Independent University, Bangladesh (IUB), Plot 16, Block B, Aftabuddin Ahmed Road, Bashundhara, Dhaka 1229, Bangladesh

are numerous examples of historical and modern approaches, in which convalescent plasma was successfully used as post-exposure prophylaxis (e.g., hepatitis, mumps, polio, measles, rabies) and/or treatment for a myriad of infectious diseases (principally, influenza, Argentine hemorrhagic fever, severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection, the Middle East respiratory syndrome coronavirus (MERS-CoV) infection, and Ebola virus infection) [1, 3–11].

Indeed, the CP constitutes a significant quick remedy in the current COVID-19 pandemic situation which has already resulted in 3,698,621 deaths out of 171,782,908 confirmed cases, and already the possible mechanisms of action of CP and the positive consequence of the CP therapy in controlling COVID-19 pathogenesis have been well noticed besides the administration of vaccines (so far 1,546,316,352 vaccine doses have been administered) [12]. Indeed, prior to the large-scale commercial use especially of the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) vaccines as well as of the repurposed antivirals and immunomodulatory agents, the CP therapy appeared to be the only strategy to immunize the SARS-CoV-2-infected serious patients (defined as the presence of dyspnea, hypoxemia, etc.) and the critical patients (with the presence of respiratory failure, septic shock, and/or multiple organ dysfunctions) within a short time [12–15]. According to several clinical studies, donors had been found to possess the anti-SARS-CoV-2 antibody titer greater than 1:1000, with the neutralizing antibody titer higher than 40 (in case of 400 mL CP administration), whereas in case of 200 mL CP administration, the neutralized antibody titer was 1:640 (together with the treatment of the antivirals and steroid) [4, 14]. It is worth noting that several trials (e.g., ClinicalTrials.gov registration no. NCT04359602, NCT04360278, NCT04344977, NCT04344015) have started to create registries in the USA to collect the plasma with titers of >1:64 from the convalescent donors without immediate reinfusion; and such plasma banking strategies can be used during the after-waves of the ongoing COVID-19 pandemic [4].

The immune plasma neutralizes the invading SARS-CoV-2 as well as also delivers the passive immunomodulatory features permitting the recipient individual to regulate the elevated cytokine levels induced by the viral infection [13]. Besides the use of several repurposed antiviral drugs including favipiravir, lopinavir and ritonavir, hydroxychloroquine, azithromycin, and remdesivir, the application of CP in SARS-CoV-1 was also found to be effective in terms of decreased mortality; and at present, such strategy is also being noticed to be very much effective in reducing the viral load with the concomitant improvement of clinical conditions in the COVID-19 patients [14, 16, 17]. While the patients who have recovered successfully from COVID-19 may play valuable role as the donors for CP therapy, the disposition of the convalescent serum prophylaxis for COVID-19 patients must comply with the availability of

donors, standard settings of blood bank facilities to process the sera, serological and viral assay facilities, appropriate prophylaxis, and therapeutic protocols along with the regulatory compliance. CP transfusion has been found to be effective especially when transfused within the first 20 days of the SARS-CoV-2 infection [14]. Therefore, both the dosage and transfusion timing are important for assuring the necessary safety and usefulness of such treatment [14]. Current review outlined the pros and cons of such application of passive immunity through the CP therapy.

Evolution and Effectiveness of Convalescent Plasma (CP) Therapy

The concept of CP infusion evolved in 1880 whereby immunity was noticed against diphtheria which had been instigated from the existing antibody titer in blood from animals purposely immunized with non-lethal doses of toxins [13]. Besides, in the early 1950s, the purified and concentrated immunoglobulins both from the healthy individuals and the recovered patients from disease imparted an opportunity for the treatment of serious infectious diseases [13]. The severe H1N1 2009 infection could be treated with CP as the viral load was found to be decreased upon transfusion as well as the cytokine storm was under control, resulting in the decline in mortality [11]. It is worth noting that meta-analysis of 1918 influenza A (H1N1) pandemic as well as the treatment of severe influenza A by H5N1 subtype infection unraveled that the CP therapy could be a potential treatment strategy [18]. The methods for the detection of the neutralizing antibodies of severe acute respiratory syndrome (SARS) convalescent sera (i.e., anti-SARS antibodies) were well endorsed in 2003, including the enzyme-linked immunosorbent assay (ELISA), neutralization assay, and Western blot; and the evaluation of the efficacy of CP therapy with severe SARS patients revealed good outcome (decrease in the viral load within a day of transfusion with simultaneous increase in the anti-SARS-CoV immunoglobulins IgM and IgG) [11, 17–21].

Indeed, the protocol for application of the CP for SARS was established in 2015 [22]. Possible sources of CP therapy against SARS-CoV-2 are human convalescent sera from individuals who have recovered from COVID-19 (Figure 1). Another option is preparations generated in certain animal hosts, such as genetically engineered cows that produce human antibody [23]. The benefits of CP therapy in the COVID-19 mitigation has been observed through the direct neutralization of invading SARS-CoV-2, regulation of the cytokine dysbiosis (precisely the cytokine storm), complement activation, and immunomodulation thereby reducing the mortality rate [13]. In a study with the hospitalized severe patients, the plasma transfusion was noticed to (1) normalize body temperature of the maximum patients, (2) the sequential organ failure




Figure 1 Preparation and pooling of the convalescent blood products (CBP). The CP manufacturing scheme presented here is adapted from Focosi et al. (2020) [4]. The convalescent donor is usually selected through the neutralizing antibody titer which is assessed through the plaque reduction neutralization test (PRNT) requiring a viable isolate, replication-competent cell lines, and skilled personnel. Alternatively, an enzyme-linked immunosorbent assay (ELISA) can also be used which targets the recombinant receptor binding domains (RBDs) of the viral anti-receptor, followed by the correlation measurements between ELISA ratios/indexes with the PRNT titers. CP can be harvested by apheresis (plasma fractionation) using the double filtration plasmapheresis (DFPP) with fractionation filter 2A20 (trial NCT04346589) or, alternatively, collecting immunoglobulins from the convalescent donors by immunoadsorption (trial NCT04264858). The pathogenic load is reduced or eliminated from the plasma by employing

assessment (SOFA) score was found to be decreased, (3) the acute respiratory distress syndrome (ARDS) was found to be eliminated in 80% cases, (4) normalized levels of C-reactive protein (CRP), alanine aminotransferase, and aspartate aminotransferase, (5) the SARS-CoV-2 load declined; and surprisingly, (6) the patients were tested to be virus negative after 12 days of transfusion [13]. Besides, as stated elsewhere, in the immunological perspective, the lymphocyte counts in the peripheral blood may significantly decrease upon CP therapy; and also, the level of the cytokines in plasma including the interleukin (IL)-6, IL-10, tumor necrosis factor (TNF)- α , and the granulocyte macrophage colony stimulating factor (GM-CSF) are likely to be reduced [1, 13, 16, 24]. Moreover, the CP therapy was found to shorten the duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support, and vasopressor support for the serious COVID-19 patients [14]. Thus, the convalescent sera obtained from the

the (1) solvent/detergent (S/D)-filtration, providing the quick inactivation of >4 logs of most enveloped viruses, or (2) by applying photoinactivation (combinations of methylene blue and visible light, theraflex, amotosalen (S-59) and UV A, and riboflavin and UV B, or (3) by using caprylic acid and octanoic acid (which also can inactivate the enveloped viruses). The next step is the pooling of CP together with the intravenous immunoglobulin (IVIg) by means of fractionation. In case of large-pool approach, the pharmaceutical-grade facilities characteristically pool 100–2500 donors to manufacture S/D-inactivated plasma; and the IVIGs are similarly prepared from pools of 2000–4000 L of plasma. In contrast, in case of minipool fractionation scale (MPFS) process, 5–10 L of plasma can be obtained. Finally, the harvested CP can be aliquoted into 200–300 mL quantities which can be preserved below -25°C prior to use [4].

recovered COVID-19 individuals who had established humoral immunity against SARS-CoV-2 consist of significant level of neutralizing antibodies against the virus which can further help eradicating the same virus from the systemic circulation as well as the pulmonary tissues in the other COVID-19 patients if CP treatment is employed.

Possible Risks Associated with CP Therapy

Although the CP therapy appears to be a potential strategy for the treatment of the severe COVID-19 patients, still some challenges rise with the side effects such as chills, fever, transfusion-related acute lung injury, and anaphylactic reactions [25]. In addition to antibodies, the convalescent whole blood (CWB) may impart the regulation of the hemorrhagic events as was noticed in case of the Ebola virus disease (EVD)

cases (Figure 1) [4, 7]. Moreover, CP infusion may have its latent threat like the aggravating hyperimmune attacks since CP therapy is completely based on the passive immunity with administering pathogen-specific immunoglobulins to the infected individuals [25, 26]. Indeed, the CP therapy can be more effective at the earlier stage of COVID-19, and hence, the peak timing of administering CP into the COVID-19 patients demands careful consideration [26]. However, with the advantage of one dose of 200 mL CP transfusion to significantly improve the clinical symptoms as well as to increase the oxyhemoglobin saturation with the concomitant neutralization of the viral load, facial red spots may be an adverse effect [27]. The other risks may include the transmission of the virus during plasma transfusion [27]. The most important risk may be the antibody-dependent entry (ADE) of the SARS-CoV-2 during CP therapy which in turn may suppress the innate antiviral state [15, 27, 28]. In addition, in case of emergency, donor screening and the conventional viral nucleic acid testing (NAT) especially for the human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) are sometimes not sufficient to guarantee the CP safety [4]. Moreover, although the convalescent plasma is habitually administered into the COVID-19 based on the experimental data with the aim of better clinical consequences, a clinical trial (PlasmAr [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04383535) number, [NCT04383535](https://clinicaltrials.gov/ct2/show/study/NCT04383535)) showed no substantial differences between the COVID-19 patients treated with the convalescent plasma and those who received placebo [29]. Such a relatively neutral result may be explained by the logic that the patients who received the CP therapy; i.e., the plasma before day 14 of the onset of symptoms are usually more likely to recover with a lower mortality rate than those who receive such CP treatment after day 14 of the development of the COVID-19 symptom. Inclusive of other clinical trials, a 75% recovery rate was noticed through the CP therapy [29]. However, the role of CP also needs to be reevaluated now that highly efficacious COVID-19 vaccines are available and a cocktail of monoclonal antibodies is likely to be effective [14, 30, 31, 32].

Conclusion

Although there are unsatisfactory results as well as some risks exist upon convalescent plasma (CP) therapy, still its application especially on the frontline COVID-19 workers (healthcare providers) may help to avoid the SARS-CoV-2 infection quickly. Indeed, the transmission dynamics of SARS-CoV-2 is so fast, and during the current pandemic, countless patients are in need of ICU and the mechanical ventilation (MV) support. As is already known, there is no specific antiviral drug against SARS-CoV-2 nor any vaccine has been globally disseminated. Thus, strategies which can reduce the requirement of ICU and MV supports are of significance.

In such circumstance, the CP therapy is undoubtedly operative for the mitigation of the disease.

Code of Availability Not applicable

Author Contributions Conceptualization: RN
Literature survey: RN, NT, CH
Formal analysis: RN
Investigation: RN
Resources: RN, NT, CH
Writing-original draft preparation: RN
Editing: RN
Visualization: RN, NT
Supervision: RN

Data Availability Not applicable

Compliance With Ethical Standards

Conflict of Interests Authors have declared that they have no conflict of interest.

Animal Research (Ethics) Not applicable

Consent to Participate (Ethics) Not applicable

Consent to Publish (Ethics) Authors have read and approved the final manuscript for publication.

References

- Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest*. 2020;130(6):2757–65. <https://doi.org/10.1172/JCI138745>.
- Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med*. 2006;145(8):599–609. <https://doi.org/10.7326/0003-4819-145-8-200610170-00139>.
- Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. *Clin Infect Dis*. 1995;21(1):150–61. <https://doi.org/10.1093/clinids/21.1.150>.
- Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. *Clin Microbiol Rev*. 2020;33(4):e00072–20. <https://doi.org/10.1128/CMR.00072-20>.
- Samad N, Sodunke TE, Banna HA, Sapkota A, Fatema AN, Iskandar K, et al. Convalescent plasma therapy for management of COVID-19: perspectives and deployment in the current global pandemic. *Risk Manag Healthc Policy*. 2020;13:2707–28. <https://doi.org/10.2147/RMHP.S281388>.
- Marson P, Cozza A, De Silvestro G. The true historical origin of convalescent plasma therapy. *Transfus Apher Sci*. 2020;59(5):102847. <https://doi.org/10.1016/j.transci.2020.102847>.
- van Griensven J, Edwards T, de Lamballerie X, Semples MG, Gallian P, Baize S, et al. *N. Engl J Med*. 2016;374(1):33–42. <https://doi.org/10.1056/NEJMoa1511812>.
- Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamini JM, et al. Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. *J Inf Secur*. 2017;74(3):302–9. <https://doi.org/10.1016/j.jinf.2016.11.009>.

9. Stokes J Jr, Wolman IJ, Carpenter HC, Margolis J. Prophylactic use of parents' whole blood in anterior poliomyelitis: Philadelphia epidemic of 1932. *Am J Dis Child*. 1935;50(3):581–95.
10. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. *N Engl J Med*. 2007;357(14):1450–1. <https://doi.org/10.1056/NEJMc070359>.
11. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis*. 2011;52(4):447–56. <https://doi.org/10.1093/cid/ciq106>.
12. WHO (World Health Organization) Coronavirus diseases (COVID-19) dashboard. Updated on 5:46pm CEST, 4 June 2021. <https://covid19.who.int/> Accessed on June 5 2021.
13. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: possible mechanisms of action. *Autoimmun Rev*. 2020;19(7):102554. <https://doi.org/10.1016/j.autrev.2020.102554>.
14. Noor R. Developmental status of the potential vaccines for the mitigation of the COVID-19 pandemic and a focus on the effectiveness of the Pfizer-BioNTech and Moderna mRNA vaccines. *Current Clinical Microbiology Reports*. 2021. <https://doi.org/10.1007/s40588-021-00162-y>.
15. Noor R. Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic. *Tzu Chi Med J*. 2020;33(1):7–12. https://doi.org/10.4103/tcmj.tcmj_100_20.
16. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *JAMA*. 2020;323(16):1582–9. <https://doi.org/10.1001/jama.2020.4783>.
17. Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. *Trials*. 2020;21(1):499. <https://doi.org/10.1186/s13063-020-04422-y>.
18. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. *PLoS Med*. 2007;4(5):e178. <https://doi.org/10.1371/journal.pmed.0040178>.
19. Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. *J Med Virol*. 2005;77(2):147–50. <https://doi.org/10.1002/jmv.20431>.
20. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005;24(1):44–6. <https://doi.org/10.1007/s10096-004-1271-9>.
21. Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J Antimicrob Chemother*. 2005;56(5):919–22. <https://doi.org/10.1093/jac/dki346>.
22. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis*. 2020;20(4):398–400. [https://doi.org/10.1016/S1473-3099\(20\)30141-9](https://doi.org/10.1016/S1473-3099(20)30141-9).
23. Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomal cattle: a phase 1 randomised, double-blind, single-dose-escalation study. *Lancet Infect Dis*. 2018;18(4):410–8. [https://doi.org/10.1016/S1473-3099\(18\)30002-1](https://doi.org/10.1016/S1473-3099(18)30002-1).
24. Noor R. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). *Arch Microbiol*. 2021;203:1943–51. <https://doi.org/10.1007/s00203-021-02265-y>.
25. Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. *J Clin Virol*. 2020;127:104358. <https://doi.org/10.1016/j.jcv.2020.104358>.
26. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, et al. Convalescent plasma: new evidence for an old therapeutic tool? *Blood Transfus*. 2016;14(2):152–7. <https://doi.org/10.2450/2015.0131-15>.
27. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;28;117(17):9490–6. <https://doi.org/10.1073/pnas.2004168117>.
28. Asaduzzaman SAI, Zakaria A, Kheya IS, Fahad N, Sikandar YB, Noor R. A comparative study between the severe acute respiratory syndrome-coronavirus-2, severe acute respiratory syndrome coronavirus, and the Middle East respiratory syndrome coronavirus. *Biomed Biotechnol Res J*. 2020;4:S65–74. https://doi.org/10.4103/bbrj.bbrj_99_20.
29. Simonovich VA, Burgos Prax LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. *N Engl J Med NEJM* oa2031304. 2020;384:619–29. <https://doi.org/10.1056/NEJMoa2031304>.
30. Kenny G, Mallon PW. COVID19- clinical presentation and therapeutic considerations. *Biochem Biophys Res Commun*. 2020;538(20):125–31. <https://doi.org/10.1016/j.bbrc.2020.11.021>.
31. Regeneron. Regeneron announces encouraging initial data from COVID-19 antibody cocktail trial in hospitalized patients on low-flow oxygen. December 29, 2020 at 4:30 PM EST. <https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-initial-data-covid-19-antibody> Accessed on January 3, 2021
32. Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. *Clin Microbiol Infect*. 2020;26(10):1436–46. <https://doi.org/10.1016/j.cmi.2020.08.005>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.